PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Anika Therapeutics, Inc. (ANIK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS0352551081
CUSIP035255108
SectorHealthcare
IndustryMedical Devices

Highlights

Market Cap$376.64M
EPS-$5.24
PEG Ratio2.23
Revenue (TTM)$169.26M
Gross Profit (TTM)$96.78M
EBITDA (TTM)$3.99M
Year Range$16.54 - $28.67
Target Price$31.00
Short %7.53%
Short Ratio14.20

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Anika Therapeutics, Inc.

Popular comparisons: ANIK vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Anika Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


500.00%600.00%700.00%800.00%900.00%1,000.00%1,100.00%December2024FebruaryMarchAprilMay
635.71%
1,102.69%
ANIK (Anika Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Anika Therapeutics, Inc. had a return of 13.64% year-to-date (YTD) and -4.56% in the last 12 months. Over the past 10 years, Anika Therapeutics, Inc. had an annualized return of -5.63%, while the S&P 500 had an annualized return of 10.87%, indicating that Anika Therapeutics, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date13.64%11.56%
1 month-0.35%7.13%
6 months24.64%17.26%
1 year-4.56%26.92%
5 years (annualized)-7.15%13.56%
10 years (annualized)-5.63%10.87%

Monthly Returns

The table below presents the monthly returns of ANIK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20243.80%3.23%4.61%1.93%13.64%
20234.76%2.23%-9.40%-10.65%5.57%-4.10%-10.20%-23.49%4.37%4.67%12.36%3.42%-23.45%
2022-11.25%2.20%-22.74%-14.26%0.98%2.67%4.66%-3.25%5.31%19.41%10.98%-6.15%-17.39%
2021-18.23%-0.84%11.14%-1.50%16.10%-7.20%-7.30%7.48%-1.32%-2.14%-6.05%-8.43%-20.84%
2020-20.71%1.58%-30.77%14.94%0.90%12.53%-3.53%5.30%-7.67%-7.83%15.88%19.74%-12.71%
201913.03%-14.11%-7.32%5.32%19.31%6.89%35.62%3.03%-3.29%28.24%-17.89%-10.29%54.27%
201823.76%-21.99%-4.48%-11.48%-7.61%-21.30%25.09%3.40%1.91%-15.22%-3.66%-2.44%-37.66%
20173.23%-7.42%-7.16%6.19%0.30%6.63%3.69%4.96%8.01%-5.81%0.90%-2.20%10.11%
2016-1.42%19.96%-0.91%2.10%3.64%13.38%-6.95%-5.37%1.29%-7.29%5.18%4.93%28.30%
2015-3.83%1.89%3.13%-17.12%-1.14%-2.08%14.74%-6.57%-10.11%21.02%8.93%-9.06%-6.33%
2014-12.81%18.33%4.39%3.99%9.57%-1.07%-9.22%-0.14%-12.71%9.49%1.87%-0.37%6.76%
20136.84%17.23%16.63%-8.06%10.56%15.18%18.29%15.07%3.24%25.03%15.00%11.09%283.90%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ANIK is 37, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of ANIK is 3737
ANIK (Anika Therapeutics, Inc.)
The Sharpe Ratio Rank of ANIK is 3939Sharpe Ratio Rank
The Sortino Ratio Rank of ANIK is 3434Sortino Ratio Rank
The Omega Ratio Rank of ANIK is 3434Omega Ratio Rank
The Calmar Ratio Rank of ANIK is 4141Calmar Ratio Rank
The Martin Ratio Rank of ANIK is 4040Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Anika Therapeutics, Inc. (ANIK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ANIK
Sharpe ratio
The chart of Sharpe ratio for ANIK, currently valued at -0.09, compared to the broader market-2.00-1.000.001.002.003.004.00-0.09
Sortino ratio
The chart of Sortino ratio for ANIK, currently valued at 0.12, compared to the broader market-4.00-2.000.002.004.006.000.12
Omega ratio
The chart of Omega ratio for ANIK, currently valued at 1.01, compared to the broader market0.501.001.502.001.01
Calmar ratio
The chart of Calmar ratio for ANIK, currently valued at -0.04, compared to the broader market0.002.004.006.00-0.04
Martin ratio
The chart of Martin ratio for ANIK, currently valued at -0.14, compared to the broader market-10.000.0010.0020.0030.00-0.14
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.34, compared to the broader market-2.00-1.000.001.002.003.004.002.34
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.31, compared to the broader market-4.00-2.000.002.004.006.003.31
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.41, compared to the broader market0.501.001.502.001.41
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.90, compared to the broader market0.002.004.006.001.90
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.93, compared to the broader market-10.000.0010.0020.0030.008.93

Sharpe Ratio

The current Anika Therapeutics, Inc. Sharpe ratio is -0.09. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Anika Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2024FebruaryMarchAprilMay
-0.09
2.34
ANIK (Anika Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Anika Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-64.90%
0
ANIK (Anika Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Anika Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Anika Therapeutics, Inc. was 95.88%, occurring on Dec 26, 2000. Recovery took 1642 trading sessions.

The current Anika Therapeutics, Inc. drawdown is 64.90%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.88%Jul 15, 1998620Dec 26, 20001642Jul 25, 20072262
-86.24%Sep 24, 2007321Dec 30, 20081154Aug 1, 20131475
-76.85%Oct 28, 2019979Sep 18, 2023
-68.42%May 13, 1993395Dec 16, 1994336May 3, 1996731
-57.96%Jan 30, 201899Jun 20, 2018340Oct 25, 2019439

Volatility

Volatility Chart

The current Anika Therapeutics, Inc. volatility is 13.97%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%December2024FebruaryMarchAprilMay
13.97%
3.10%
ANIK (Anika Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Anika Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items